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The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface
molecules. As a pattern-recognition receptor capable of binding a diverse range of ligands, it is typically expressed at low levels
under normal physiological conditions in the majority of tissues. In contrast, the lung exhibits high basal level expression of
RAGE localised primarily in alveolar type I (ATI) cells, suggesting a potentially important role for the receptor in maintaining
lung homeostasis. Indeed, disruption of RAGE levels has been implicated in the pathogenesis of a variety of pulmonary disorders
including cancer and ﬁbrosis. Furthermore, its soluble isoforms, sRAGE, which act as decoy receptors, have been shown to be a
useful marker of ATI cell injury. Whilst RAGE undoubtedly plays an important role in the biology of the lung, it remains unclear
as to the exact nature of this contribution under both physiological and pathological conditions.
1.Introduction
The receptor for advanced glycation end products (RAGE)
is a member of the immunoglobulin superfamily [1].
The receptor itself is composed of an extracellular region
containing one “V”-type and two “C”-type immunoglobulin
domains.Thisisfollowedbyahydrophobictransmembrane-
spanningdomainwhichinturnneighboursahighlycharged,
short cytoplasmic domain that is essential for post-RAGE
signalling (Figure 1). This has been termed “full-length”
or membrane RAGE (mRAGE). In addition, a number of
isoforms have been identiﬁed (see below).
RAGE was initially identiﬁed and characterised for its
ability to bind advanced glycation end products (AGEs),
adducts formed by glycoxidation that accumulate in disor-
ders such as diabetes [2]. Subsequently, RAGE has also been
shown to be a pattern recognition receptor, recognising fam-
ilies of ligands rather than a single polypeptide. Such ligands
include amyloid ﬁbrils, amphoterins, S100/calgranulins, and
Mac-1 [3, 4].
In the majority of healthy adult tissues, RAGE is
expressedatalowbasallevel.Theup-regulationofRAGEhas
been associated with a diverse range of pathological events,
from atherosclerosis to Alzheimer’s disease [5]. However,
the exact function of RAGE in the lung has yet to be
fully characterised. Uniquely, pulmonary tissues express
remarkably high basal levels of RAGE suggesting that RAGE
may have a number of functions in the lung distinct from
that which it holds in other tissues (Figure 2). Whilst the
current body of research indicates important roles in both
pulmonary physiology and numerous pathological states,
additional work is required to clarify those inconsistencies
which currently exist in the literature and further elucidate
the important role of RAGE in the lung. This review aims
to critically assess the current body of evidence relating
to RAGE in the lung and stimulate further research and
discussion on its functions in the pulmonary context.
2. RAGE Isoforms
In addition to its full-length, membrane-bound form
(mRAGE), an increasing number of isoforms of RAGE have
been identiﬁed (Figure 1). In particular, RAGE has been
shown to exist in a soluble isoform termed soluble RAGE
(sRAGE). Whilst the sRAGE isoform contains the same2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of RAGE and the generation of some of its isoforms commonly found in the lung. In addition to its
full-length form (mRAGE), RAGE also exists in a soluble form (sRAGE) which lacks the transmembrane and cytosolic domains found in
mRAGE. Production of sRAGE isoforms is via either proteolytic cleavage, which gives rise to cleaved RAGE (cRAGE) or alternative splicing
at exon 9 resulting in a C-truncated form termed endogenous secretory RAGE (esRAGE).
V-type and C-type regions found in mRAGE, it lacks
the transmembrane and cytosolic domains. Consequently,
sRAGE is found in the extracellular space and is capable
of binding RAGE ligands prior to their interaction with
mRAGE. sRAGE is produced primarily by two mechanisms:
removalofthetransmembraneregionviaalternativesplicing
and cleavage from the membrane by proteolysis.
Studies have illustrated that alternative splicing at exon
9 gives rise to a C-truncated form termed endogenous
secretory RAGE (esRAGE or RAGE v1) [6]. Proteolytic
cleavage at the cell surface results in the production of a
further soluble isoform termed cleaved RAGE (cRAGE) [7].
Recent ﬁndings by Raucci et al. [8] suggest that this process
is mediated by ADAM10, a membrane metallopeptidase.
Notably, both soluble isoforms are capable of binding the
same RAGE ligands and in this sense their functions are
equivalent. In this way, it has been proposed that sRAGE acts
as a decoy receptor, preventing the interaction of mRAGE
with its ligands.
Furthermore, it has been shown that the expression
of many isoforms in tissues or cell lines is dependent
on the cell type. Indeed, Gefter and colleagues [9]h a v e
recentlyillustratedthatcertainlungisoformspossess distinct
epitopes which were not found elsewhere. Interestingly, non-
lung cells and tissues were found to express mRNA which
was more than three times the size of that expressed in
the lung. Moreover, the majority of cell lines were revealed
to express a cell line isoform whilst lacking the isoform
foundpredominantlyinthelung.Theseﬁndingssuggestthat
those RAGE isoforms unique to the lung may exhibit both
structural and functional diﬀerences. However, it is currently
unclear as to the speciﬁc mechanisms which give rise to
any lung-restricted isoforms. Undoubtedly, the role of RAGE
under both physiological and pathological settings involves
elaborate interaction between the numerous isoforms. Thus,
further elucidation of the expression of all isoforms of RAGE
is essential.
3. LocalisationandPhysiological Role of
RAGEin the Lung
Initial immunostaining data of bovine tissues showed RAGE
to be expressed in pulmonary endothelium, bronchial and
vascular smooth muscle, alveolar macrophages, leiomy-
ocytes, and the visceral pleural surface [10]. Using poly-
clonal antibodies and specimens from human thoracoscopy,Journal of Biomedicine and Biotechnology 3
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Figure 2: Tissue distribution of RAGE. (a) Relative number of expressed-sequence clones per million identiﬁed in tissue and species-speciﬁc
databases[11].Thetablewasupdatedon07/20/09.(b)QuantitativeanalysisofRAGEmRNAexpressioninhealthyhumantissue.Twosetsof
RAGE-speciﬁc primers, RAqu 2( b l a c k )a n dR A q u3 (white), were used to compare RAGE expression in 16 human tissues of healthy donors
in quantitative RT-PCR analysis. The transcript numbers of RAGE were compared with the transcript numbers of GAPDH in 2μLc D N A .
The mean and SEM of two separate light cycler runs are displayed (adapted from [12]).
Morbini and coworkers [13] later observed RAGE in bron-
chiolar epithelia, alveolar type II cells, macrophages, and
some endothelia. However, in both rat and human lungs,
RAGE has also been suggested to colocalise with markers
speciﬁc to type I alveolar epithelial cells [12, 14]. However,
this contrasts with Katsuoka’s ﬁndings [15] that RAGE
mRNA expression was predominantly restricted to alveolar
typeII(ATII)pneumocytesinrats.ExpressionofbothRAGE
protein and mRNA in A549, a human lung adenocarcinoma
cell line with alveolar type II-like properties, has been
s u g g e s t e db ys o m eg r o u p s[ 16, 17], while others were unable
toconﬁrmRAGEtobepresentinA549cellsatbaseline(Nina
Demling personal communication).
FurthersupportingevidenceforthelocalisationofRAGE
to alveolar epithelial type I (ATI) cells was provided by
Dahlinetal.[18]whoillustratedthatRAGEwasdiﬀerentially
expressed in rat type I cells. Similarly, the rat type I-like
cell line, R3/1, has also been shown to express high levels of
RAGE [19]. Collectively, this suggests RAGE being a marker
for type I pneumocytes rather than the type II phenotype.
Within the ATI cell, RAGE has been shown to be
speciﬁcally localised towards the basal cell membrane [12,
14, 20]. Given its high expression in the lung and speciﬁc
localisation in ATI cells, an important role for RAGE in
maintaining lung homeostasis is likely. However, the exact
roleofRAGEinlungphysiologyhasyettobefullyelucidated.4 Journal of Biomedicine and Biotechnology
Demling and coworkers [12] have shown that HEK293 cells
overexpressing RAGE adhere much faster to collagen IV,
a n dt oag r e a t e re x t e n tw h e nc o m p a r e dt om o c kt r a n s f e c t e d
cells. Furthermore, the degree of adherence was decreased
in the presence of an anti-RAGE antibody. Similarly, in
A549 cells, blockade of RAGE inhibited the adhesion onto
collagen and intact extracellular matrix [17]. Preincubation
with sRAGE was found to reduce this eﬀect, although alone
it was found to have no eﬀect on cell adhesion, suggesting
that this function is mediated by RAGE in its full-length
form. Moreover, expression of RAGE has also been shown
to promote spreading of adherent cells on collagen IV.
The speciﬁcity of this RAGE-collagen IV interaction was
underlined by the fact that adherence on ﬁbronectin and
laminin was ineﬃcient [12]. In addition, the ﬁndings of
Bartling et al. [21] that RAGE-transfected lung cancer cells
exhibited epithelial growth on collagen layers suggest that
this interaction is of functional importance. Most recently, it
has been shown that RAGE and collagen IV are colocalised
at the basement membrane of normal mouse lungs [22].
Observations by Hori et al. [23] that a RAGE-amphoterin
interaction is involved in neurite outgrowth during brain
development further support a possible role for RAGE in
cell-extracellular matrix interactions.
Using siRNA techniques it was illustrated that knock-
down of RAGE in A549 cells and human pulmonary ﬁbrob-
lasts resulted in increased migration as evaluated by chemo-
taxis migration and scratch wound healing assays [17].
Furthermore, both modiﬁed cell types exhibited increased
proliferation. Of note, the eﬀect of RAGE knockdown on
migration was more pronounced in ﬁbroblasts whilst con-
versely epithelial cells adopted greater proliferative capacity,
suggesting that the speciﬁc role of RAGE may vary from one
cell type to another.
In a developmental setting, it has been shown in rat
lungs that levels of mRAGE and sRAGE at both the mRNA
and protein level exhibit a gradual increase from foetal
(E19) through to adulthood [24]. Given that the newborn
rat lung is not fully alveolarised, this increase in RAGE
levels may correspond to alveolarisation and expansion of
the ATI cell population. Additionally, since sRAGE has been
shown to inhibit RAGE dependent epithelial spreading in
vitro [12], the deﬁciency of sRAGE at these early stages of
development may serve to promote spreading of ATI cells
during development of the alveolus.
Together, these ﬁndings indicate that RAGE may assist
ATI cells to acquire a spread-out morphology and in doing
so ensure eﬀective gas exchange and alveolar stability. Given
its apparently important role in modulating adhesion of
alveolar epithelial cells to the basement membrane, a role for
RAGE in pathologies such as cancer and ﬁbrosis, in which
these interactions are altered or impaired, appears likely.
4. RAGEandLungCancer
Recent evidence indicates that RAGE plays an impor-
tant role in cancer. RAGE ligands, which include the
S100/calgranulins and high-mobility group box 1 (HMGB1)
protein, are expressed and secreted by cancer cells and
cause cellular activation, resulting in enhanced expression
of cytokines and growth factors, increased cell migration,
and activation of the transcription factor, NF-κB[ 25]. In
tumours, because blockade of RAGE reduces tumour cell
growth and metastases, it might be expected that the most
invasive tumours would have the highest levels of RAGE.
While this appears to be the case for prostate, colon, and
gastric tumours, curiously, lung cancers, among the most
invasive of tumours, are reported to express low levels of
RAGE [26, 27] .R e d u c e dl e v e l so fR A G Eh a v eb e e no b s e r v e d
in non-small cell lung carcinoma (NSCLC) compared with
the normal lung [21, 28–33]. Only one publication reported
abundant RAGE expression in lung tumour specimens by
microarray [34]. Down-regulation of RAGE, on the other
hand, correlated well with higher tumour stages [21].
Moreover, overexpression of full-length human RAGE in
H358 lung cancer cells resulted in reduced tumour growth
compared to that in dominant-negative RAGE expressing
cells in vivo [35]. Recently, it was found that esRAGE, the
splice variant that is secreted and acts as an antagonist, is also
down-regulated in NSCLC [36].
Amphoterin (HMGB1) is a high mobility group I non-
histone DNA-binding protein that can be secreted into the
extracellular space during certain stages of development
or in necrotic cells, where it triggers inﬂammation [37].
Although it is unclear to what extent amphoterin is located
in the extracellular space of tumour cells, the interaction of
amphoterin with RAGE has been suggested to contribute
to tumour growth and especially, to invasive migration and
metastasis [26]. Blockade of the amphoterin-RAGE inter-
action decreased matrix metalloproteinase (MMP) activity
and inhibited tumour growth and metastases [38]. MMPs
which are able to degrade almost all extracellular matrix
components have been shown to associate with increased
metastatic potential in many cancer types [39]. Bartling et
al. [21] demonstrated that overexpression of RAGE in lung
cancer cells without additional application of amphoterin
does not mediate an increased tumour growth in athymic
mice. Overexpression of full-length human RAGE in lung
cancer cells even showed a diminished in vitro proliferation
in monolayer cell cultures compared with cells expressing
the cytoplasmic deletion mutant of RAGE (ΔcytoRAGE) or
mock transfected cells.
Other RAGE-ligands are also suggested to be expressed
in lung cancer. S100P overexpression in NSCLC associated
with poor survival was reported in two studies [40, 41].
Furthermore, overexpression of S100P but not S100A2 in
the HTB-58 NSCLC cell line increased its transendothelial
migration [41]. S100A4 and S100A6 were also found to be
up-regulated in lung tumours [34, 42]. Reduced E-cadherin
expression combined with higher S100A4 expression was
associated with poor prognosis due to increased metastasis
in pulmonary adenocarcinoma [43].
RAGE ligands are widely overexpressed in lung cancer,
while the receptor itself seems to be down-regulated or
cleaved proteolytically. The broad range of ligands with
which RAGE interacts and the multiple alternative mecha-
nisms ofactionoftheseligands make it diﬃculttodetermine
the speciﬁc mechanisms involved in particular functions.Journal of Biomedicine and Biotechnology 5
It appears that interference with RAGE ligands will be of
therapeutic beneﬁt in lung cancer, but further study is
needed to fully understand the role of RAGE and its ligands
in this aggressive cancer pathology.
5. RAGE Alteration during Exposure
to CigaretteSmoke and Radon
The two leading risk factors for lung cancer are cigarette
smoke and radon exposure [44]. The group of Jian Tong
extensively studied alterations of RAGE and its ligands by
proteomics, after exposure of rats to these noxious agents
[45–47]. They found that RAGE and S100A6 were up-
regulated in a dose-dependant manner when rats were
exposed to radon for cumulative doses up to 400 working
level months (WLM) [45]. A similar eﬀect was observed
when rats were exposed to cigarette smoke twice daily for
up to 4 months [46]. When combining the two insults,
that is, exposing the rat to cigarette smoke (75 days) plus
radon (200WLM), similar alterations in protein expression
resulted [47]. By immunohistochemistry the RAGE signal
was predominantly observed at the alveolar interstitium
and epithelial cells. Reynolds et al. [48] demonstrated that
RAGE, S100A12, and amphoterin were up-regulated in a
rat (R3/1) and human (A549) alveolar epithelial cells and
macrophages (RAW 264.7) following exposure to cigarette
smokeextract(CSE).TheyfurtherconﬁrmedelevatedRAGE
levels in the lungs of mice exposed to cigarette smoke for 6
months.RAGElevelwasinﬂuencedbydiﬀerentialexpression
of transcription factors such as TTF-1 and Egr-1 and that
activation of RAGE and Egr-1 by cigarette smoke synergis-
tically elaborated both RAGE and its ligands to maintain
RAGE signalling [48]. The same group also reported that Ras
was induced in R3/1 cells after exposure to CSE, resulting
in up-regulation of NF-κB, leading to increased secretion of
proinﬂammatory cytokines such as TNFα,I L - 1 β,a n dI L - 8
[49]. When cells were treated with siRNA for RAGE, Ras
and NF-κB activation was decreased [50]. In human lungs
with lesions associated with smoking, immunohistochemical
studies have shown that bronchiolar epithelia, areas of
alveolarbronchialisation,reactivepneumocytes,andalveolar
macrophages all exhibit widespread RAGE reactivity [13].
S100A12 was found to be expressed in polymorphonu-
clear granulocytes and in extracellular ﬂuid, whilst low
reactivity was seen in bronchiolar epithelia and a number
of macrophages. Moreover, both the number of carboxy-
methyl-lysine positive cells and intensity of expression were
measurably enhanced in epithelial and inﬂammatory cells of
the lungs of smokers.
6. RAGEand Pulmonary Fibrosis
Similar to lung cancer, ﬁbrotic processes are disorders in
which cell attachment and cell communication are critical
events. RAGE has been implicated in the ﬁbrotic process in
a number of tissues, including the peritoneum, kidney, and
liver [51–53], where it has been shown to promote ﬁbrosis.
In the lung, evidence continues to accumulate suggesting an
important role for RAGE in pulmonary ﬁbrosis, although
data is conﬂicting if RAGE has a protective function or is
indeed a culprit.
In animal models of pulmonary ﬁbrosis, both membrane
RAGE and sRAGE protein levels have been shown to be
reduced following treatment with bleomycin, asbestos, or
silica [54–56]. In the case of bleomycin injury, loss of
mRAGE was seen within 24 hours [55]a n dar e d u c t i o n
in sRAGE observed as early as day 2 [54], with levels of
both remaining reduced at day 7 [54, 55]. The deleterious
eﬀects of asbestos on expression of both mRAGE and sRAGE
were evident within 24 hours and maintained to day 14
following treatment [55]. In common with asbestos, silica
was found to induce a loss of RAGE which was apparent in
samples isolated two weeks after treatment [56]. A similar
decrease in RAGE has also been illustrated in ATI cells
isolated from rat lung slices treated with CdCl2 and TGF-β1
[57]. Investigations by Englert et al. [55] have shown that
RAGE-deﬁcient (RAGE −/−) mice spontaneously develop
ﬁbrosis-like alterations in lungs, exhibiting enhanced levels
of collagen I and increased hydroxyproline content. Further-
more, following treatment with asbestos, these mice develop
a ﬁbrosis which is more severe compared to control mice.
Similar ﬁndings have been illustrated in lung
homogenates and broncho-alveolar lavage ﬂuid (BALF)
from patients suﬀering form idiopathic pulmonary ﬁbrosis
(IPF). Both Englert et al. [55] and Queisser et al. [17]
report that RAGE protein levels in lung homogenates
were reduced in comparison to healthy donor samples. A
lower concentration of sRAGE was also found in BALF
of IPF patients [58]. Moreover, the RAGE gene has been
shown to be signiﬁcantly down-regulated in IPF lungs
[55, 59, 60]. Together, these ﬁndings suggest that loss of
RAGE may serve to promote ﬁbrosis in the lung or that
RAGE down-regulation is a result of this pathology.
In contrast, He and colleagues [61] report that RAGE
−/− mice were resistant to bleomycin induced lung injury
with enhanced survival rates and lower ﬁbrotic scores. They
showed that protein levels of the pro-ﬁbrotic cytokines
TGF-β1 and PDGF in BALF failed to increase in RAGE
−/− mice following bleomycin treatment, in contrast to
wildtype mice. Additionally, HMGB1 increased in mice
treated with bleomycin. Coupled to this, ATII cells cultured
in the presence of HMGB1 were found to undergo epithelial-
mesenchymal transition (EMT). In cells isolated from RAGE
−/− mice, HMGB1 failed to induce EMT suggesting a
potential role for RAGE signalling in HMGB1-induced EMT.
These ﬁndings are in accordance with the traditionally held
view of RAGE as being proﬁbrotic [51–53] and that the
RAGE expression is controlled by cytokines [62].
Findings by Morbini et al. [13] lend further evidence
to a role for RAGE in promoting ﬁbrosis. In immuno-
histochemical studies of lung samples from IPF patients,
overexpression of RAGE was found in reactive pneumocytes,
bronchiolar metaplastic epithelium, and endothelium. Inter-
estingly, overexpression was most apparent in ﬁbroblastic
foci. Additionally, in a recent study by Chen et al. [63]
it was shown that AGE levels in rat lungs were increased
signiﬁcantly following bleomycin instillation. Interestingly,6 Journal of Biomedicine and Biotechnology
when formation of AGEs was blocked through treatment
withaminoguanidine,bleomycin-inducedﬁbrosiswasatten-
uated.Itisunclear,however,astowhatextentthisinvolvesits
receptor, RAGE.
In those suﬀering from cystic ﬁbrosis (CF), injury to
the lung as a consequence of sustained inﬂammation is the
most prevalent cause of morbidity and mortality [64]. The
S100 family of calcium binding proteins has been implicated
in this process. It has been suggested that these proteins
mediate their proinﬂammatory eﬀects in CF via RAGE.
Studies by Foell et al. [65] have shown that S100A12 is
locally expressed by inﬁltrating neutrophils in the lungs of
CF patients. Furthermore, it has been illustrated that levels
of S100A12 in the sputum of CF patients are extremely high
[65, 66]. During acute infectious exacerbations, serum levels
were found to be increased in comparison to controls [65].
Interestingly, intravenous antibiotic treatment successfully
reduced S100A12 levels. In addition, RAGE expression in
CF neutrophils was signiﬁcantly enhanced along with a
reduction in levels of sRAGE [66]. Together, this points
towardsanimportantroleforRAGEinneutrophilassociated
airway inﬂammation in CF.
Currently, it is unclear as to the exact role of RAGE in
ﬁbrosis of the lung. A number of studies undertaken using
animal models of ﬁbrosis have produced conﬂicting results.
These ﬁndings highlight the acknowledged limitations of
such models [67] and consequently limit the extent to which
inference can be drawn from them. Furthermore, whilst a
number of studies report a loss of RAGE under experimental
conditions of ﬁbrosis, it is unclear as to whether this is due to
a down-regulation of RAGE itself or simply a loss of alveolar
type I epithelial cells, the primary expresser of RAGE.
7. RAGEand Acute Lung Injuryand Acute
Respiratory Distress Syndrome
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS), a more severe manifestation, are char-
acterised by deterioration of the alveolar-capillary barrier
together with impaired alveolar ﬂuid clearance (AFC) [68].
Core to this process is the damage of ATI cells, which
under physiological conditions help maintain the integrity
of the alveolar-capillary barrier in addition to transporting
sodium and thus, ensuring an intact AFC. Given this, RAGE,
which is expressed primarily in ATI cells, has been suggested
as a biomarker for ALI and ARDS [54, 69].
Several diﬀerent animal models of ALI resulted in
increased RAGE levels in the BALF [69–74]. However, the
level of response varied depending on the experimental
model used. Su et al. [72] reported that RAGE levels in
BALF were elevated 58-, 22-, and 13-fold after intratracheal
instillation of hydrochloric acid, lipopolysaccharide (LPS),
and Escherichia coli in mice. The same study also showed
an increase in BALF RAGE after hyperoxia (95% O2,9 6h ) .
Hyperoxia (75% O2, 96h) was recently reported to up-
regulate both membrane RAGE and sRAGE protein in
mice as well as RAGE mRNA in alveolar epithelial cells
in primary culture under hyperoxic conditions [73]. RAGE
k n o c k - o u tm i c e ,h o w e v e r ,w e r ep r o t e c t e df r o mh y p e r o x i a -
induced mortality, had less protein in BALF and diminished
lung ﬂuid, fewer total BALF cells and reduced secretion
of proinﬂammatory cytokines [73]. Parmley and colleagues
[74] demonstrated that lung injury induced by cytokine (IL-
1α and IFN-γ) instillation was associated with increased
inﬂammation, tissue damage, and elevation of RAGE,
ICAM-1, VCAM-1, and LDH levels (in BALF). Antagonists
of α4/β1a n dαL/β2 integrins suppressed adhesion of MNP
and modulated release of RAGE and LDH [74].
In contrast to these direct models of lung injury, ALI
induced indirectly using either MHC I antibodies (i.v.)o r
thiourea (i.p.) failed to alter RAGE levels in the BALF [72].
Uchida et al. [69] had previously demonstrated that RAGE
levels in the BALF and serum varied with the severity of
lunginjuryfollowingi.t.instillationofHClintorats,whereas
RAGE was not detected in serum from LPS-instilled animals.
This suggests that diﬀerent pathways might be involved in
RAGE release into the BALF and serum, depending on the
nature of the insult. When studying LPS-induced lung injury
in mice, Zhang et al. [71] conﬁrmed that sRAGE levels in
the BALF are increased 24 hours after LPS instillation (but
not after 6h). They also reported that sRAGE injected i.p.
1hour after LPS instillation was able to attenuate BALF total
cell count, neutrophils, lung permeability index, and NF-κB
activity. Moreover, sRAGE treatment signiﬁcantly attenuated
up-regulation of several (but not all) proinﬂammatory
cytokines in BALF, while with the exception of MIP-1β,n o
signiﬁcant diﬀerence in cytokine serum levels between the
LPS and the LPS plus sRAGE groups was observed [71].
These results suggest that sRAGE blockade of HMGB-1-
induced increase in proinﬂammatory cytokines is restricted
to the lung.
When comparing RAGE levels in pulmonary oedema
ﬂuid and plasma from patients with ALI/ARDS with a group
of patients with hydrostatic pulmonary oedema, the RAGE
levels in ALI/ARDS were signiﬁcantly higher than those
frompatientswithhydrostaticpulmonaryoedemaorcontrol
[69]. Furthermore, RAGE levels in the alveolar oedema
ﬂuid were signiﬁcantly higher than plasma in patients
with pulmonary oedema. This ﬁnding suggested that the
source of RAGE in these samples was predominantly from
the lungs rather than from the circulation. Additionally,
poorer clinical outcomes in patients with ALI have been
shown to be strongly correlated with higher baseline plasma
sRAGE levels [75], whilst both airspace and perfusate sRAGE
levels appeared to be negatively correlated with AFC [76,
77]. In support of this, the RAGE ligand S100A12 was
enhanced in pulmonary tissues of ARDS patients, coupled
with an increased concentration of S100A12 in BALF [78],
whilst HMGB1, another RAGE ligand has been shown to
induceneutrophilaccumulation,lungoedema,andreleaseof
cytokines [79, 80]. Given that RAGE is the primary receptor
through which these ligands act, blockade of this interaction
would appear to be of beneﬁt in assisting in the resolution of
lung injury.
From these ﬁndings it can be speculated that RAGE is
releasedfromATIcellsduringALI/ARDSeitherviaapoptotic
events or controlled shedding, for example, via MMPs fromJournal of Biomedicine and Biotechnology 7
the epithelium of inﬁltrated leukocytes [81]. RAGE can then
potentially participate in a negative feedback after excessive
inﬂammation by acting as a decoy receptor for, for example,
HMGB1, which is know to be up-regulated in response to
LPS and causes an inﬂammatory response manifested by
increasing production of cytokines [82].
8. RAGE and Other Pulmonary Disorders
Sarcoidosis, a disease state characterised by noncaseating
granulomae, has been illustrated to exhibit expression of
RAGE together with its ligands [13, 83]. Furthermore, it
was shown that a speciﬁc polymorphism, which is associated
with greater transcriptional activity of RAGE, is more
prevalent in sarcoidosis patients compared with healthy
subjects [83].
In immunohistochemical studies, overexpression of
RAGE was most prominent in epithelia associated with
inﬂammatory cell aggregates in organising pneumonia [13].
In addition, in a recent study RAGE deﬁciency was shown to
protectagainstpneumococcalpneumoniainamurinemodel
[84]. RAGE −/− mice intranasally inoculated with Strepto-
coccuspneumoniaeexhibitedimprovedsurvivaltogetherwith
lower bacterial load in the lungs after 16hours and reduced
distribution of bacteria to the blood and spleen. Moreover,
macrophages isolated from RAGE −/− mice possessed an
elevated killing capacity, suggesting a possible mechanism
by which RAGE deﬁciency may serve to ameliorate the
deleterious eﬀects of S. pneumoniae. In line with the ﬁndings
of Morbini et al. [13], expression of RAGE in lung tissue of
mice treated with S. pneumoniae was found to be enhanced.
Additionally, inﬂammation of the lung was reduced in mice
lacking RAGE, whilst migration of neutrophils to the lungs
was alleviated. RAGE −/− mice also displayed reduced
activation of coagulation, suggesting that RAGE potentially
acts, at least in part, as a mediator of coagulation [85].
Similarly, in inﬂuenza A virus model of pneumonia, RAGE
(−/−) mice exhibited enhanced resistance to pneumonia
as illustrated by increased survival and improved viral
clearance. This was coupled with a superior cellular T cell
response and neutrophil activation [86]. Implicit in the
inﬂammatory response to infection is the careful balance
between beneﬁt and harm. Collectively, these results indicate
thatRAGEmayperturbthisbalancegivingrisetoasustained
inﬂammatory response.
As t u d yb yC a l f e ee ta l .[ 87] of patients undergoing
lung transplantation indicated that plasma sRAGE levels
were associated with a more prolonged duration of mechan-
ical ventilation and ICU length of stay. Moreover, when
measured with 4hours of allograft reperfusion, it proved
a better prognostic marker for these short-term outcomes
when compared to the clinical diagnosis of primary graft
dysfunction. Sternberg and coworkers’ [88] investigations
lend further support to suggest an important role for RAGE
signalling in lung injury following transplantation surgery.
Through blockade of RAGE, they explored the functional
relevance of RAGE signalling in animals subjected to pul-
monary ischemia and reperfusion injury (IR). Of note, IR is
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Figure 3: RAGE is central to many fundamental biological
processes in the lung. Expression of RAGE has been shown to
promote spreading of adherent cells on collagen IV and in doing
so may ensure eﬀective gas exchange. RAGE-expressing epithelial
cells exhibit diminished proliferative capacity compared to non-
expressing cells. Cells overexpressing RAGE adhere much faster
to collagen IV, and to a greater extent when compared to mock
transfected cells suggesting an important role in cell-extracellular
matrix interactions.
thought to be directly linked to primary graft dysfunction,
one of the principal sources of morbidity following lung
transplantation. They revealed that animals treated with
sRAGE exhibited enhanced oxygenation and a reduction in
capillary leakage, coupled with improved histological injury.
TheseﬁndingswerefurtherreinforcedbythatfactthatRAGE
−/− mice also failed to develop pulmonary reperfusion
injury. In addition, production of IL-8 and activation of
NF-κB, both implicated in the pathogenesis of IR, failed to
increase in contrast to controls. Whilst these results infer
a role for RAGE in inﬂammatory signalling, surprisingly,
RAGE at mRNA and protein levels were found to decrease
following injury. Clearly, further investigations are required
to fully elucidate the exact role of RAGE signalling in this
pathology.
9. Concluding Remarks
Unlike in other tissues, RAGE is highly expressed in the lung
under normal physiological conditions. Given this, it has
been suggested that RAGE may exhibit properties restricted
solely to the pulmonary environment. Indeed, studies have
illustrated that RAGE possesses a number of important
physiological roles in the lung including modulation of cell
spreading, adhesion to ECM components, proliferation, and
migration (Figure 3). Moreover, disturbance of this basal
expression level appears to result in impaired functioning
of RAGE, giving rise to pathological states including cancer
and ﬁbrosis. However, it remains unclear as to whether
this is associated with down-regulation or up-regulation of
expression at mRNA and protein levels with current studies
reporting conﬂicting results.8 Journal of Biomedicine and Biotechnology
In addition, evidence continues to accumulate for the
existence of numerous isoforms of RAGE. It is likely that
many of these isoforms exhibit unique properties, with
expression in some instances limited to speciﬁc cells or
tissues. Notably, its soluble isoforms have been shown to be
an important marker of injury to ATI cells. Furthermore,
sRAGE is known to act as a decoy receptor binding ligands
which otherwise would interact with full-length, membrane-
bound RAGE. Clearly, developing a greater understanding
of each isoform’s expression, function, and interaction is
essential in order to establish an accurate picture of the
behaviour of RAGE in the lung.
Undoubtedly, RAGE and its isoforms play an essential
role in the biology of the lung under both physiological
and pathological conditions. However, it is vital that future
studies address the relative contribution of both RAGE
and its isoforms whilst continuing to ensure that those
experimental models used reﬂect conditions in vivo.
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